SP
SPRC.US Scisparc Ltd
- Market cap
- USD 810K
- P/E
- 0.0x
- P/B
- 0.22x
- ROE
- -416.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is SPRC.US undervalued?
Graham numberThe Graham number of Scisparc Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Scisparc Ltd fundamental analysis
No fundamental analysis for Scisparc Ltd yet.
Scisparc Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop…
Full company profileScisparc Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Scisparc Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 487K | 838K | 498K | 550K | 1.07M | 1.35M | 2.88M | 1.31M | 856K | 1.36M |
| Gross Profit | - | 482K | 691K | 319K | 386K | 1.04M | 1.03M | 2.20M | 506K | 631K | 876K |
| Operating Income | -2.00M | -5.75M | -9.71M | -4.11M | -3.29M | -5.77M | -7.38M | -5.77M | -7.32M | -8.75M | -8.97M |
| EBITDA | -2.00M | -5.75M | -6.93M | -3.73M | -2.39M | -5.74M | -2.36M | -5.31M | -6.97M | -12.3M | -8.70M |
| Net Income | -1.99M | -6.24M | -8.52M | -5.36M | -3.51M | -5.80M | -2.59M | -5.12M | -6.28M | -12.2M | -16.4M |
| EPS | -0.05 | -0.05 | -1.07 | -0.81 | -2.46 | -66 | -27 | -23 | -9.71 | -0.88 | -30 |
| Balance Sheet | |||||||||||
| Total Assets | 1.24M | 9.57M | 4.56M | 1.15M | 2.56M | 9.92M | 10.6M | 11.2M | 10.3M | 7.62M | 18.5M |
| Total Liabilities | 672K | 1.18M | 4.48M | 1.14M | 1.13M | 1.78M | 4.16M | 1.60M | 1.41M | 2.48M | 7.22M |
| Shareholders' Equity | 573K | 8.13M | 185K | 14.0K | 1.43M | 8.14M | 6.45M | 7.61M | 8.15M | 4.24M | 3.95M |
| Cash & Short-term Investments | 675K | 9.20M | 1.49M | 870K | 1.95M | 6.88M | 3.57M | 5.08M | 2.06M | 4.59M | 4.44M |
| Total Debt | - | - | 1.85M | 500K | 465K | 504K | 27.0K | 76.0K | 46.0K | 366K | 2.68M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.48M | -4.58M | -7.13M | -4.70M | -4.31M | -5.06M | -7.92M | -5.89M | -5.10M | -4.14M | -11.7M |
| Capital Expenditure | 4.16K | 44.0K | 17.0K | 1.00K | 35.0K | 35.0K | 4.87M | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.48M | -4.62M | -7.15M | -4.70M | -4.31M | -5.10M | -12.8M | -5.89M | -5.10M | -4.14M | -11.7M |
| Ratios | |||||||||||
| ROE | -347.5% | -76.8% | -4,607.0% | -38,300.0% | -245.2% | -71.3% | -40.2% | -67.3% | -77.1% | -287.3% | -416.8% |
| ROA | -159.9% | -65.3% | -186.9% | -464.6% | -136.9% | -58.5% | -24.4% | -45.8% | -60.7% | -159.8% | -88.9% |
| Net Profit Margin | - | -1,282.1% | -1,017.1% | -1,076.7% | -637.6% | -542.7% | -192.4% | -177.9% | -481.2% | -1,422.8% | -1,210.9% |
| Debt to Equity | - | - | 9.99x | 35.71x | 0.33x | 0.06x | 0.00x | 0.01x | 0.01x | 0.09x | 0.68x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Scisparc Ltd dividends
Scisparc Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:9 on Mar 4, 2026.
Who owns Scisparc Ltd
- Insiders 0.00%
- Institutions 1.44%
- Public & others 98.56%
- Shares outstanding 2.46M
- Free float 576K
Top institutions holding SPRC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 21.2K | 3.66% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 16.5K | 2.84% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 11.1K | 1.90% | 0.00% | Jun 2026 |
| UBS Group AG | 4.52K | 0.78% | +43.61% | Jun 2026 |
| JPMorgan Chase & Co | 211.00 | 0.04% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 200.00 | 0.03% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 32.00 | 0.01% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 12.00 | 0.00% | +1,100.00% | Jun 2026 |
| Strategic Investment Solutions Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Scisparc Ltd company profile
- Company name
- Scisparc Ltd
- Ticker
- SPRC.US
- ISIN
- IL0010951403
- Exchange
- USA Stocks
- Listed since
- Aug 30, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- Tower A, Tel Aviv-Yafo, Israel, 6971916
- Phone
- 972 7 334 47180
- Website
- scisparc.com
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Scisparc Ltd management
3- Mr. Oz Adler CPACEO & CFO · born 1987
- Mr. Amitai WeissPresident & Director · born 1962
- Dr. Adi Zuloff-Shani Ph.D.Chief Technologies Officer · born 1967